Endologix Appoints Chief Medical Officer

Endologix Inc., developer and marketer of aortic disorder treatments, has appointed Matthew Thompson, M.D., as chief medical officer effective December 2016. He succeeds David Deaton, M.D., who will continue to work with the company as a consultant.  
 
“We are excited to have Dr. Thompson join the Endologix leadership team. He is an international thought leader in vascular surgery and endovascular therapies, and shares our dedication to patient care,” said John McDermott, CEO of Endologix. “His deep experience treating a wide variety of aortic conditions will benefit our clinical programs, physician training initiatives and product development. In addition, Dr. Thompson is one of our most experienced Nellix users and clinical investigators, providing an excellent background across EVAR and EVAS.”
 
“I want to thank Dr. Deaton for his service as chief medical officer and his significant contributions to the company over the past few years. We look forward to continuing to work with Dr. Deaton in the future,” McDermott added.
 
Most recently, Thompson served as professor of vascular surgery at St. George’s, University of London and St. George’s Vascular Institute. He trained at Cambridge, St. Bartholomew’s Hospital, the University of Leicester and Adelaide. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. Thompson is also the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He was chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services and is a founder of the British Society for Endovascular Therapy. Thompson is also a council member of the Vascular Society, chairman of the Vascular Society Annual Scientific Meeting and elected president for 2018.

“I look forward to this new chapter in my career and am thrilled to be joining one of the most innovative companies in endovascular aortic therapy. Endologix’s passion and commitment to patient safety and outcomes makes the position a natural fit that allows me to continue serving patients with aortic disorders, but now on a global scale,” Thompson said.

Endologix Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Irvine, Calif.-based company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80 percent, making it a leading cause of death in the United States.